European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
Babjuk M., Burger M., Compérat E. M., Gontero P., Mostafid A. H., Palou J., van R. B. W. G., Rouprêt M., Shariat Sh., Sylvester R., Zigeuner R., Capoun O., Cohen D., Escrig J. L. D., Hernández V., Peyronnet B., Seisen T., Soukup V.
European Urology
Vol.76, Issue5, P. 639-657
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.eururo.2019.08.016
Аннотация:
Context: This overview presents the updated European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). Objective: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. Evidence acquisition: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB i
Ключевые слова:
Bacillus Calmette-Guérin; Bacillus Calmette-Guérin unresponsive; Bladder cancer; Cystoscopy; Diagnosis; European association of urology; Follow-up; Guidelines; Intravesical chemotherapy; Prognosis; Radical cystectomy; Transurethral resection; Urothelial carcinoma
antineoplastic agent; BCG vaccine; molecular marker; adjuvant chemotherapy; adjuvant therapy; bacterial strain; BCG vaccination; bladder biopsy; bladder papilloma; cancer adjuvant therapy; cancer chemotherapy; cancer classification; cancer epidemiology; cancer grading; cancer patient; cancer prognosis; cancer recurrence; cancer staging; cancer surgery; carcinoma in situ; combination drug therapy; cystectomy; cystoscopy; diagnostic imaging; drug efficacy; drug indication; European Union; fluorescence imaging; follow up; high risk population; histology; human; intermediate risk population; interrater reliability; intrarater reliability; low risk population; medical history; minimal residual disease; non muscle invasive bladder cancer; optimal drug dose; pathology; patient counseling; physical disease by body function; physical examination; postoperative care; practice guideline; priority journal; prostate biopsy; prostate urethra; randomized controlled trial (topic); recurrence risk; Rev
Язык текста: Английский
ISSN: 1873-7560
Babjuk M.
Burger M.
Compérat E. M.
Gontero P.
Mostafid A. H.
Palou J.
van R. B. W. G. Rhijn B.W.G.
Rouprêt M.
Shariat Sh. Sharokh 1973-
Sylvester R.
Zigeuner R.
Capoun O.
Cohen D.
Escrig J. L. D.
Hernández V.
Peyronnet B.
Seisen T.
Soukup V.
Бабйук М.
Бургер М.
Cомпéрат Е. М.
Гонтеро П.
Мостафид А. Х.
Палоу Й.
ван Р. Б. W. Г. Рхийн Б.W.Г.
Роупрêт М.
Шариат Ш. Шарох 1973-
Сyлвестер Р.
Зигеунер Р.
Cапоун О.
Cохен Д.
Есcриг Й. Л. Д.
Хернáндез В.
Пеyроннет Б.
Сеисен Т.
Соукуп В.
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
Текст визуальный непосредственный
European Urology
Elsevier Science Publisher B.V.
Vol.76, Issue5 P. 639-657
2019
Обзор
Bacillus Calmette-Guérin Bacillus Calmette-Guérin unresponsive Bladder cancer Cystoscopy Diagnosis European association of urology Follow-up Guidelines Intravesical chemotherapy Prognosis Radical cystectomy Transurethral resection Urothelial carcinoma
antineoplastic agent BCG vaccine molecular marker adjuvant chemotherapy adjuvant therapy bacterial strain BCG vaccination bladder biopsy bladder papilloma cancer adjuvant therapy cancer chemotherapy cancer classification cancer epidemiology cancer grading cancer patient cancer prognosis cancer recurrence cancer staging cancer surgery carcinoma in situ combination drug therapy cystectomy cystoscopy diagnostic imaging drug efficacy drug indication European Union fluorescence imaging follow up high risk population histology human intermediate risk population interrater reliability intrarater reliability low risk population medical history minimal residual disease non muscle invasive bladder cancer optimal drug dose pathology patient counseling physical disease by body function physical examination postoperative care practice guideline priority journal prostate biopsy prostate urethra randomized controlled trial (topic) recurrence risk Rev
Context: This overview presents the updated European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). Objective: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. Evidence acquisition: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB i